Fixed dosing of her antibodies

Abstract

The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.

1 . A method for treating cancer comprising administering one or more fixed dose(s) of a HER antibody to a human patient in an amount effective to treat the cancer. 
     
     
         2 . The method of  claim 1  wherein the antibody binds to a HER receptor selected from the group consisting of EGFR, HER2, and HER3. 
     
     
         3 . The method of  claim 2  wherein the antibody binds to HER2. 
     
     
         4 - 6 . (canceled) 
     
     
         7 . The method of  claim 1  wherein the HER antibody comprises the variable light and variable heavy amino acid sequences in SEQ ID Nos. 3 and 4, respectively. 
     
     
         8 . The method of  claim 1  wherein the HER antibody is pertuzumab. 
     
     
         9 . The method of  claim 1  wherein the fixed dose is in the range from about 20 mg to about 2000 mg of the HER antibody. 
     
     
         10 . The method of  claim 9  wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of the HER antibody. 
     
     
         11 - 14 . (canceled) 
     
     
         15 . The method of  claim 1  wherein a fixed dose of the HER antibody is administered to the patient approximately every week, approximately every 2 weeks, approximately every 3 weeks, or approximately every 4 weeks. 
     
     
         16 . The method of  claim 15  wherein a fixed dose of the HER antibody is administered to the patient approximately every 3 weeks. 
     
     
         17 - 24 . (canceled) 
     
     
         25 . The method of  claim 1  wherein the cancer displays HER expression, amplification, or activation. 
     
     
         26 . (canceled) 
     
     
         27 . The method of  claim 1  wherein the cancer is metastatic breast cancer (MBC). 
     
     
         28 . The method of  claim 1  wherein the cancer is non-small cell lung cancer (NSCLC). 
     
     
         29 . (canceled) 
     
     
         30 . The method of  claim 1  wherein the cancer is colorectal cancer. 
     
     
         31 . The method of  claim 1  comprising administering a second therapeutic agent to the patient. 
     
     
         32 . The method of  claim 31  wherein the second therapeutic agent is selected from the group consisting of chemotherapeutic agent, different HER antibody, antibody directed against a different tumor associated antigen, anti-hormonal compound, cardioprotectant, cytokine, EGFR-targeted drug, anti-angiogenic agent, tyrosine kinase inhibitor, COX inhibitor, non-steroidal anti-inflammatory drug, farnesyl transferase inhibitor, antibody that binds oncofetal protein CA 125, HER2 vaccine, another HER targeting therapy, Raf or ras inhibitor, doxorubicin HCL liposome injection, topotecan, taxane, dual tyrosine kinase inhibitor, TLK286, EMD-7200, a medicament that treats nausea, a medicament that prevents or treats skin rash or standard acne therapy, a body temperature-reducing medicament, and a hematopoietic growth factor. 
     
     
         33 - 36 . (canceled) 
     
     
         37 . A method of treating cancer in a human patient comprising administering at least one fixed dose of pertuzumab to the patient, wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of pertuzumab. 
     
     
         38 . The method of  claim 37  wherein a fixed dose of pertuzumab is administered to the patient approximately every 3 weeks. 
     
     
         39 . The method of  claim 37  wherein the cancer is selected from the group consisting of ovarian cancer, peritoneal cancer, fallopian tube cancer, metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), prostate cancer, and colorectal cancer. 
     
     
         40 . The method of  claim 37  wherein the fixed dose is selected from the group consisting of 420 mg, 525 mg, 840 mg, and 1050 mg of pertuzumab. 
     
     
         41 . An article of manufacture comprising a vial containing a fixed dose of a HER antibody, wherein the fixed dose is selected from the group consisting of approximately 420 mg, approximately 525 mg, approximately 840 mg, and approximately 1050 mg of the HER antibody. 
     
     
         42 - 48 . (canceled)